New drug duo tested in fight against Tough-to-Treat blood cancer
NCT ID NCT05083208
Summary
This early-stage trial tested the safety and best dose of a two-drug combination (parsaclisib and chidamide) for people with a fast-growing type of blood cancer called peripheral T-cell lymphoma that has come back or stopped responding to standard treatments. The main goals were to see how well patients tolerated the drugs and to find the safest dose for future studies. The trial was terminated early and only enrolled 12 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.